Division of Vascular Surgery, University of Toronto, Toronto, Ontario, Canada.
Division of Vascular Surgery, Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto, Ontario, Canada.
JAMA Netw Open. 2019 Jul 3;2(7):e196578. doi: 10.1001/jamanetworkopen.2019.6578.
Knowledge regarding the long-term outcomes of elective treatment of abdominal aortic aneurysm (AAA) using endovascular aortic repair (EVAR) is increasing. However, data with greater than 10 years' follow-up remain sparse and are lacking from population-based studies.
To determine the long-term outcomes of EVAR compared with open surgical repair (OSR) for elective treatment of AAA.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective, population-based cohort study used linked administrative health data from Ontario, Canada, to identify all patients 40 years and older who underwent elective EVAR or OSR for AAA repair from April 1, 2003, to March 31, 2016, with follow-up terminating on March 31, 2017. A total of 17 683 patients were identified using validated procedure and billing codes and were propensity score matched. Analysis was conducted from June 26, 2018, to January 16, 2019.
Elective EVAR or OSR for AAA.
The primary outcome was overall survival. Secondary outcomes were major adverse cardiovascular event-free survival, defined as being free of death, myocardial infarction, or stroke; reintervention; and secondary rupture.
Among 17 683 patients who received elective AAA repairs (mean [SD] age, 72.6 [7.8] years; 14 286 [80.8%] men), 6100 (34.5%) underwent EVAR and 11 583 (65.5%) underwent OSR. From these patients, 4010 well-balanced propensity score-matched pairs of patients were defined, with a mean (SD) age of 73.0 (7.6) years and 6583 (82.1%) men. In the matched cohort, the mean (SD) follow-up was 4.4 (2.7) years, and maximum follow-up was 13.8 years. The overall median survival was 8.9 years. Compared with OSR, EVAR was associated with a higher survival rate up to 1 year after repair (91.0% [95% CI, 90.1%-91.9%] vs 94.0% [95% CI, 93.3%-94.7%]) and a higher major adverse cardiovascular event-free survival rate up to 4 years after repair (69.9% [95% CI, 68.3%-71.3%] vs 72.9% [95% CI, 71.4%-74.4%]). Cumulative incidence of reintervention was higher among patients who underwent EVAR compared with those who underwent OSR at the 7-year follow-up (45.9% [95% CI, 44.1%-47.8%] vs 42.2% [95% CI, 40.4%-44.0%]). Survival analyses demonstrated no statistically significant differences in long-term survival, reintervention, and secondary rupture for patients who underwent EVAR compared with those who underwent OSR. Kaplan-Meier analysis suggested superior long-term major adverse cardiovascular event-free survival among patients who underwent EVAR compared with those who underwent OSR (32.6% [95% CI, 26.9%-38.4%] vs 14.1% [95% CI, 4.0%-30.4%]; stratified log-rank P < .001) during a maximum follow-up of 13.8 years.
Endovascular aortic repair was not associated with a difference in long-term survival during more than 13 years' maximum follow-up. The reasons for these findings will require studies to consider specific graft makes and models, adherence to instructions for use, and types and reasons for reintervention.
越来越多的知识涉及使用血管内主动脉修复(EVAR)对腹主动脉瘤(AAA)进行择期治疗的长期结果。然而,随访时间超过 10 年的数据仍然很少,并且缺乏基于人群的研究。
确定与开放手术修复(OSR)相比,EVAR 治疗 AAA 的长期结果。
设计、设置和参与者:这项回顾性、基于人群的队列研究使用来自加拿大安大略省的链接行政健康数据,确定了所有 40 岁及以上的患者,这些患者接受了择期 EVAR 或 OSR 治疗 AAA 修复,从 2003 年 4 月 1 日至 2016 年 3 月 31 日,随访截止日期为 2017 年 3 月 31 日。使用经过验证的手术和计费代码识别了 17683 名患者,并进行了倾向评分匹配。分析于 2018 年 6 月 26 日至 2019 年 1 月 16 日进行。
AAA 的择期 EVAR 或 OSR。
主要结果是总生存率。次要结果是主要不良心血管事件无事件生存率,定义为无死亡、心肌梗死或中风;再次干预;和继发性破裂。
在接受择期 AAA 修复的 17683 名患者中(平均[SD]年龄,72.6[7.8]岁;14286[80.8%]名男性),6100 名(34.5%)接受了 EVAR,11583 名(65.5%)接受了 OSR。从这些患者中,确定了 4010 对匹配良好的倾向评分匹配患者,平均(SD)年龄为 73.0(7.6)岁,6583 名(82.1%)为男性。在匹配队列中,平均(SD)随访时间为 4.4(2.7)年,最大随访时间为 13.8 年。中位总体生存率为 8.9 年。与 OSR 相比,EVAR 与修复后 1 年时更高的生存率相关(91.0%[95%CI,90.1%-91.9%]与 94.0%[95%CI,93.3%-94.7%]),与修复后 4 年时更高的主要不良心血管事件无事件生存率相关(69.9%[95%CI,68.3%-71.3%]与 72.9%[95%CI,71.4%-74.4%])。与 OSR 相比,EVAR 组患者在 7 年随访时再次干预的累积发生率更高(45.9%[95%CI,44.1%-47.8%]与 42.2%[95%CI,40.4%-44.0%])。生存分析表明,EVAR 组与 OSR 组患者在长期生存、再次干预和继发性破裂方面无统计学显著差异。Kaplan-Meier 分析表明,EVAR 组患者在长达 13.8 年的最长随访期间具有更好的长期主要不良心血管事件无事件生存率(32.6%[95%CI,26.9%-38.4%]与 14.1%[95%CI,4.0%-30.4%];分层对数秩 P <.001)。
在超过 13 年的最长随访期间,EVAR 与长期生存无差异。这些发现的原因将需要研究考虑特定的移植物制造和型号、对使用说明的遵守以及再干预的类型和原因。